# August J. Troendle, MD

> August J. Troendle, MD founded Medpace in Cincinnati in July 1992 and continues as its chief executive officer and chairman. His career includes the FDA, Sandoz, private equity ownership transitions, a 2016 Nasdaq listing, and decades of international expansion while maintaining a Cincinnati base.

- **Role:** Founder, Chief Executive Officer and Chairman at Medpace
- **Organizations:** Medpace, US Food and Drug Administration, Sandoz, Coherus BioSciences, Xenon Pharmaceuticals, LIB Therapeutics, CinCor Pharma, CinRx Pharma
- **Nationality:** American
- **Education:** Doctor of Medicine (MD), University of Maryland School of Medicine, Master of Business Administration (MBA), Boston University
- **Known for:** Founded Medpace in July 1992 and has remained its CEO and chairman., EY Entrepreneur Of The Year Ohio Valley regional winner in 2015., Led Medpace through its August 2016 Nasdaq IPO.

## Career timeline

- **1986-1987** — Worked as a Medical Review Officer at the FDA.
- **1987-1992** — Served in management at Sandoz, now associated with Novartis.
- **1992-07** — Founded Medpace in Cincinnati; became CEO and chairman.
- **2011** — CCMP acquired an ownership interest in Medpace.
- **2014** — Cinven announced a majority investment; Troendle continued to lead and retained a minority investment alongside management.
- **2015** — Won an EY Entrepreneur Of The Year award in the Ohio Valley region.
- **2016-08** — Medpace completed its Nasdaq IPO at $23 per share.
- **2018-08** — Cinven announced its final sell-down; Troendle continued to lead Medpace.
- **2021-08** — Jesse Geiger became president; Troendle remained CEO and chairman.
- **2022** — Attended a Warsaw office expansion celebration with Susan Burwig during Medpace’s thirtieth anniversary year.

## Achievements

- Founded Medpace in July 1992 and has remained its CEO and chairman.
- EY Entrepreneur Of The Year Ohio Valley regional winner in 2015.
- Led Medpace through its August 2016 Nasdaq IPO.

## Latest updates

- **2026-09** — Medpace announced on September 22 that third-quarter 2026 results would be released on October 21, followed by an October 22 conference call; these events were forthcoming as of October 20.
- **2026-07** — Medpace reported second-quarter revenue of $707.3 million, up 17.2% year over year; Troendle discussed demand and employee growth on the earnings call.

## Links

- Website: https://investor.medpace.com/board-member/august-j-troendle-md/

---

Profile page: https://yespress.io/august-troendle
Published by YesPress — https://yespress.io
Last updated: 2026-10-20